Shares of ChromaDex Co. (NASDAQ:CDXC - Get Free Report) hit a new 52-week high on Wednesday after LADENBURG THALM/SH SH raised their price target on the stock from $6.80 to $8.10. LADENBURG THALM/SH SH currently has a buy rating on the stock. ChromaDex traded as high as $8.16 and last traded at $8.38, with a volume of 3436130 shares trading hands. The stock had previously closed at $5.60.
A number of other research firms also recently weighed in on CDXC. Roth Mkm lifted their price target on ChromaDex from $6.00 to $8.00 and gave the company a "buy" rating in a research note on Wednesday, November 6th. StockNews.com upgraded ChromaDex from a "buy" rating to a "strong-buy" rating in a research note on Monday, February 24th.
Read Our Latest Stock Report on CDXC
Insider Activity at ChromaDex
In other ChromaDex news, Director Frank L. Jaksch, Jr. sold 37,161 shares of the business's stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the sale, the director now directly owns 244,179 shares in the company, valued at approximately $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 9.64% of the company's stock.
Hedge Funds Weigh In On ChromaDex
Institutional investors have recently made changes to their positions in the stock. USA Financial Formulas acquired a new position in shares of ChromaDex in the fourth quarter worth $25,000. State of Wyoming acquired a new position in ChromaDex in the fourth quarter valued at $39,000. Mercer Global Advisors Inc. ADV acquired a new position in ChromaDex in the fourth quarter valued at $53,000. Truist Financial Corp acquired a new position in ChromaDex in the fourth quarter valued at $54,000. Finally, FMR LLC acquired a new position in ChromaDex in the third quarter valued at $55,000. 15.41% of the stock is owned by institutional investors and hedge funds.
ChromaDex Stock Up 0.1 %
The stock has a market capitalization of $598.68 million, a price-to-earnings ratio of 770.77 and a beta of 2.21. The company has a 50 day moving average of $5.77 and a 200 day moving average of $5.20.
About ChromaDex
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
Featured Articles
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
